Achieve Life Sciences Inc
ACHV2.820USD
-0.050-1.74%
收盘 09/19, 16:00（美东）报价延迟15分钟
140.11M总市值
亏损市盈率 TTM
关于 Achieve Life Sciences Inc 公司
Achieve Life Sciences, Inc. 是一家后期临床制药公司。该公司致力于开发和商业化用于戒烟和尼古丁成瘾的西替西尼克林。该公司的候选产品西替西尼克林是一种天然存在的植物性生物碱。西替西尼克林的结构与尼古丁相似，具有明确的双重作用机制，既有激动作用又有拮抗作用。西替西尼克林是一种部分激动剂，可与大脑中的 α-4 β-2 烟碱乙酰胆碱受体高亲和力结合。通过其双重作用的部分激动剂/部分拮抗剂活性，西替西尼克林有助于减少对尼古丁的渴望、戒断症状以及与吸烟相关的奖励和满足感。该公司正在开发西替西尼克林作为戒烟和尼古丁成瘾治疗的辅助手段，以解决处方药和非处方 (OTC) 产品的局限性。
公司简介
公司代码ACHV
公司名称Achieve Life Sciences Inc
上市日期Oct 12, 1995
CEOMr. Richard Stewart
员工数量25
证券类型Ordinary Share
年结日Oct 12
公司地址22722 29Th Dr. Se
城市SEATTLE
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编98021
电话14256861500
网址https://achievelifesciences.com/
公司代码ACHV
上市日期Oct 12, 1995
CEOMr. Richard Stewart
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Cindy Jacobs, M.D., Ph.D.
Dr. Cindy Jacobs, M.D., Ph.D.
President, Director, Chief Medical Officer
President, Director, Chief Medical Officer
115.58K
+248.00%
Ms. Jaime Xinos
Ms. Jaime Xinos
Chief Commercial Officer
Chief Commercial Officer
74.44K
+183.11%
Mr. Mark K. Oki
Mr. Mark K. Oki
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
10.00K
--
Mr. Thomas B. King
Mr. Thomas B. King
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
--
--
Mr. Richard Stewart
Mr. Richard Stewart
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Nancy R. Phelan
Ms. Nancy R. Phelan
Independent Director
Independent Director
--
--
Dr. Kristen B. Slaoui, Ph.D.
Dr. Kristen B. Slaoui, Ph.D.
Independent Director
Independent Director
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas Sellig
Mr. Thomas Sellig
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Cindy Jacobs, M.D., Ph.D.
Dr. Cindy Jacobs, M.D., Ph.D.
President, Director, Chief Medical Officer
President, Director, Chief Medical Officer
115.58K
+248.00%
Ms. Jaime Xinos
Ms. Jaime Xinos
Chief Commercial Officer
Chief Commercial Officer
74.44K
+183.11%
Mr. Mark K. Oki
Mr. Mark K. Oki
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
10.00K
--
Mr. Thomas B. King
Mr. Thomas B. King
Interim Executive Chairman of the Board
Interim Executive Chairman of the Board
--
--
Mr. Richard Stewart
Mr. Richard Stewart
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Nancy R. Phelan
Ms. Nancy R. Phelan
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月10日 周三
更新时间: 9月10日 周三
持股股东
股东类型
持股股东
持股股东
占比
Propel Bio Management, LLC
19.28%
Franklin Advisers, Inc.
8.73%
Alyeska Investment Group, L.P.
6.86%
The Vanguard Group, Inc.
4.21%
Contrarian Alpha Management, L.L.C.
3.02%
其他
57.91%
持股股东
持股股东
占比
Propel Bio Management, LLC
19.28%
Franklin Advisers, Inc.
8.73%
Alyeska Investment Group, L.P.
6.86%
The Vanguard Group, Inc.
4.21%
Contrarian Alpha Management, L.L.C.
3.02%
其他
57.91%
股东类型
持股股东
占比
Venture Capital
19.28%
Hedge Fund
15.74%
Investment Advisor
13.99%
Investment Advisor/Hedge Fund
11.32%
Individual Investor
4.49%
Research Firm
1.09%
Bank and Trust
0.01%
其他
34.07%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
148
20.35M
40.95%
+719.94K
2025Q1
153
17.96M
40.70%
-1.67M
2024Q4
146
23.37M
67.97%
-345.80K
2024Q3
139
24.25M
71.81%
-1.59M
2024Q2
126
25.87M
76.52%
+2.27M
2024Q1
101
23.59M
82.23%
+11.64M
2023Q4
89
9.84M
47.28%
+1.08K
2023Q3
88
8.70M
44.68%
-1.20M
2023Q2
86
9.15M
47.00%
+473.03K
2023Q1
79
7.95M
51.30%
+1.20M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Propel Bio Management, LLC
2.45M
4.94%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
2.46M
4.95%
-1.39M
-36.17%
Mar 31, 2025
Alyeska Investment Group, L.P.
421.00K
0.85%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.72M
3.46%
-32.78K
-1.87%
Mar 31, 2025
Contrarian Alpha Management, L.L.C.
1.54M
3.11%
+105.00K
+7.30%
May 15, 2024
Patrick (Callahan J. III)
1.53M
3.08%
--
--
Apr 15, 2025
Simplify Asset Management Inc
217.84K
0.44%
--
--
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
公告日期
类型
比率
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
Jul 30, 2020
Merger
20→1
